Candesartan in Peripheral Neuropathy

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Background:

Chemotherapy induced peripheral neuropathy (CIPN) is often painful, and is caused by neurotoxic chemotherapy including vincristine. It is a cause of significant impairment in quality of life in patients surviving to a solid cancer or malignant lymphoma. The only recognized prevention is based on pre-existing neuropathy and early detection of neuropathic signs and symptoms in individuals subjected to neurotoxic chemotherapy, justifying sometimes a change in the therapeutic strategy when other molecules are available. It seems obvious that to identify early markers of CIPN and to develop preventive therapeutic strategies, are priorities for improving patients' quality of life and enable them to follow optimal treatment.

Purpose:

To describe in patients treated for non-Hodgkin's type B malignant lymphoma with multidrug therapy containing vincristine, the impact of candesartan on the occurrence of neuropathy measured by the variation of TNSc (Total Neuropathy Score clinical version, evaluating clinical signs of neuropathy)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Limoges
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Patients aged 18 years and over and to be treated with Vincristine for non-Hodgkin B lymphoma (first line treatment)

• All the patients have to be treated with the same chemotherapy protocol (CHOP with or without Rituximab) to avoid confounding factors

• Normal renal function as measured by CKD-EPI > 30 mmol / min / 1.73 m2

• Serum potassium < 5.5 mmol / l

• Systolic arterial pressure > 100 mm Hg (lying and standing position)

• affiliated with a social security

• For women of childbearing age: under "highly effective" contraception and negative pregnancy test at inclusion. Highly effective contraception:

• Combined hormonal contraceptive (containing estrogen and progesterone) (oral, intravaginal, or transdermal) or only progesterone (oral, injectable or implantable),

Exclusion Criteria:

• Patients with pre-existing neuropathy, Chronic ethylism, HIV infection, etc.

• Patients under guardianship or unable for another reason to give informed consent.

• Intolerance to sartans

• Intolerance to excipients : galactose , lactose.

• Patients already treated with ACE inhibitors, ARBs or/and diuretics sparing